Summit Pharmaceuticals International

A mix of drugs
AI drug discovery platform CytoReason enters Japan via partnership with Sumitomo's SPI
By Adam Ang | 05:03 am | September 30, 2021
This collaboration will work with an unnamed pharma company in Japan to know how its drugs behave compared to rival products.